Drug profile · INN
lipegfilgrastim
LONQUEX
lipegfilgrastim (LONQUEX) is a granulocyte colony stimulating factor receptor agonist. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L03) L03AA14
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — lipegfilgrastim
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
lipegfilgrastim (LONQUEX) is a granulocyte colony stimulating factor receptor agonist. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN lipegfilgrastim
Brand LONQUEX
Mechanism Granulocyte colony stimulating factor receptor agonist
Target Granulocyte colony-stimulating factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L03)
ATC code L03AA14
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lipegfilgrastim?
lipegfilgrastim (LONQUEX) is a granulocyte colony stimulating factor receptor agonist. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for lipegfilgrastim?
LONQUEX is a marketed brand name for lipegfilgrastim. Check FDA Drugs@FDA for the current US label holder and prescribing information.